Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

A Phase I Randomized Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

A study in healthy male and female participants of non-childbearing potential who are overweight or obese.

Study Overview

• Status: Completed
• Conditions: Healthy Participants
• Intervention / Treatment: Drug: AZD6234; Drug: Placebo; Combination product: Acetaminophen

Detailed Description

The study will comprise of:

• A Screening Period of maximum 28 days.
• A Treatment Period during which participants will be resident at the Clinical Unit from three days before (Day -3 ) Investigational Medicinal Product (IMP) administration (Day 1) until at least 4 days (96 hours) after IMP administration, participants will then be discharged on the morning of Day 5.
• Weekly outpatient visits on Days 8, 15, 22, 29, and 36 for blood sample collection, Electrocardiogram (ECGs), and adverse events (AE) recording.
• A Follow-up Visit 6 weeks (Day 43) after the last IMP dose.

Furthermore, 3 dose levels of AZD6234 for Subcutaneous (SC) administration (Cohorts 1 to 3) and one dose level for Intravenous (IV) administration (Cohort 4) are planned to be investigated in healthy participants who are overweight or obese. The IV cohort (Cohort 4) can begin in parallel or after Cohort 3. One dose level for SC administration is planned to be investigated in Japanese participants only (Cohort 5), and up to 3 additional dose levels for SC administration are planned to be investigated in healthy participants (Cohort 6 to 8). Depending on the findings, additional (optional) dose level cohorts may be added at the discretion of the Sponsor.

• Study Type: Interventional
• Enrollment (Actual): 54
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Glendale, California, United States, 91206
      • Research Site
  • Maryland
    • Brooklyn, Maryland, United States, 21225
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Provision of signed and dated, written informed consent prior to any study specific procedures.
• Healthy male and female participants aged 18 to 55 years with suitable veins for cannulation or repeated venipuncture.

• Females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit, must not be lactating and must be of non childbearing potential, confirmed at the Screening Visit by fulfilling one of the following criteria:

  (i) Post menopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and Follicle stimulating hormone (FSH) levels in the post menopausal range.

(ii) Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

• Have a body mass index (BMI) of 25 to 35 kg/m2 inclusive (at the time of screening) and weigh at least 50 kg.

For the Japanese cohort(s):

• Participant is a native of Japan; defined as having both parents and four grandparents who are Japanese. This includes second and third generation subjects of Japanese descent whose parents or grandparents are living in a country other than Japan.
• Have a BMI of 23 to 35 kg/m2 inclusive (at the time of screening) and weigh at least 50 kg.

Exclusion Criteria:

• History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study, including:

  (i) Gastroparesis (or similar) requiring treatment, or (ii) Previous surgery of the upper gastrointestinal tract, or (iii) Cardiovascular disease, including but not limited to sick sinus syndrome, valvular disease, and cardiomyopathy, or (iv) Neuromuscular or neurogenic disease, or (v) Severe vitamin D deficiency < 12 ng/dL (as assessed by screening laboratory results or history), or (vi) Type 1 or type 2 diabetes mellitus.

• History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
• Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP.

• Any laboratory values with the following deviations:

  (i) Alanine aminotransferase > Upper limit of normal (ULN) (ii) Aspartate aminotransferase > ULN (iii) eGFR < 60 ml/min/1.73 m2 (calculated using the CKD EPI formula) (iv) White blood cell count < LLN (v) Hemoglobin < LLN (vi) Total calcium or corrected calcium/ionized calcium < LLN or > ULN

• Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:

  (i) Systolic Blood pressure (BP) < 90 mmHg or > 140 mmHg. (ii) Diastolic BP < 50 mmHg or > 90 mmHg. (iii) Heart rate < 55 or > 85 beats per minute (bpm)

• History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD6234.
• Has received another new chemical entity (defined as a compound which has not been approved for marketing) within at least 30 days or 5 half-lives (whichever is longer) of the first administration of IMP in this study. The period of exclusion begins 30 days or 5 half-lives after the last visit in the previous study, whichever is the longest.
• Participants who are vegans or have medical dietary restrictions.
• Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Double

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1; Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC	Drug: AZD6234; Participants will receive a single dose of AZD6234 as a solution via SC or IV injection; Drug: Placebo; Participants will receive matching volumes of the placebo as a solution via SC or IV injection; Combination product: Acetaminophen; Participants will receive a single dose of acetaminophen as part of a meal
Experimental: Cohort 2; Participants will receive a single dose of AZD6234 via an SC injection and matching volume of the placebo as a solution via SC injection	Drug: AZD6234; Participants will receive a single dose of AZD6234 as a solution via SC or IV injection; Drug: Placebo; Participants will receive matching volumes of the placebo as a solution via SC or IV injection; Combination product: Acetaminophen; Participants will receive a single dose of acetaminophen as part of a meal
Experimental: Cohort 3; Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection	Drug: AZD6234; Participants will receive a single dose of AZD6234 as a solution via SC or IV injection; Drug: Placebo; Participants will receive matching volumes of the placebo as a solution via SC or IV injection; Combination product: Acetaminophen; Participants will receive a single dose of acetaminophen as part of a meal
Experimental: Cohort 4; Participants will receive single ascending doses of AZD6234 via IV injection and matching volumes of the placebo as a solution via IV injection	Drug: AZD6234; Participants will receive a single dose of AZD6234 as a solution via SC or IV injection; Drug: Placebo; Participants will receive matching volumes of the placebo as a solution via SC or IV injection; Combination product: Acetaminophen; Participants will receive a single dose of acetaminophen as part of a meal
Experimental: Cohort 5; One dose level for SC administration is planned to be investigated for Japanese participants only	Drug: AZD6234; Participants will receive a single dose of AZD6234 as a solution via SC or IV injection; Drug: Placebo; Participants will receive matching volumes of the placebo as a solution via SC or IV injection; Combination product: Acetaminophen; Participants will receive a single dose of acetaminophen as part of a meal
Experimental: Cohort 6; Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection	Drug: AZD6234; Participants will receive a single dose of AZD6234 as a solution via SC or IV injection; Drug: Placebo; Participants will receive matching volumes of the placebo as a solution via SC or IV injection; Combination product: Acetaminophen; Participants will receive a single dose of acetaminophen as part of a meal
Experimental: Cohort 7; Participants will receive single ascending doses of AZD6234 via SC injection and matching volumes of the placebo as a solution via SC injection	Drug: AZD6234; Participants will receive a single dose of AZD6234 as a solution via SC or IV injection; Drug: Placebo; Participants will receive matching volumes of the placebo as a solution via SC or IV injection; Combination product: Acetaminophen; Participants will receive a single dose of acetaminophen as part of a meal
Experimental: Cohort 8; Participants will receive AZD6234 via SC injection and matching volumes of placebo as a solution via SC injection	Drug: AZD6234; Participants will receive a single dose of AZD6234 as a solution via SC or IV injection; Drug: Placebo; Participants will receive matching volumes of the placebo as a solution via SC or IV injection; Combination product: Acetaminophen; Participants will receive a single dose of acetaminophen as part of a meal

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with AEs and Serious Adverse Events(SAE)	The safety and tolerability of AZD6234 following subcutaneous and/or intravenous administration of single ascending doses in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Screening until Follow up (Day 43)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum observed plasma drug concentration (Cmax)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Area under the plasma concentration-time (AUClast)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Area under plasma concentration-time curve from zero to infinity (AUCinf)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Time to reach maximum observed concentration (tmax)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Terminal rate constant (λz)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Terminal elimination half-life (t½λz)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Total body clearance of drug from plasma (IV dosing only) (CL)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Apparent total body clearance of drug from plasma (SC dosing only) (CL/F)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Volume of distribution based on the terminal phase (IV dosing only) (Vz)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Apparent volume of distribution based on the terminal phase (SC dosing only) (Vz/F)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Dose-normalized AUClast (AUClast/D)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Dose-normalized AUCinf (AUCinf/D)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Dose-normalized Cmax (Cmax/D)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Time of last observed (quantifiable) concentration (tlast)	The pharmacokinetics of AZD6234 in plasma following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	From Day 1 until Follow up (Day 43)
Prevalence and incidence of anti-drug antibodies (ADAs) to AZD6234	The immunogenicity following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy participants, including Japanese participants, who are overweight or obese will be assessed.	Day 1, Day 15, Day 29 and at Follow up (Day 43)
ADA titer	The immunogenicity following subcutaneous and/or intravenous administration of single ascending doses of AZD6234 in healthy subjects, including Japanese subjects, who are overweight or obese will be assessed	Day 1, Day 15, Day 29 and at Follow up (Day 43)

Collaborators and Investigators

• Sponsor: AstraZeneca

Study record dates

Study Major Dates

• Study Start (Actual): September 20, 2022
• Primary Completion (Actual): December 19, 2023
• Study Completion (Actual): December 19, 2023

Study Registration Dates

• First Submitted: August 19, 2022
• First Submitted That Met QC Criteria: August 19, 2022
• First Posted (Actual): August 22, 2022

Study Record Updates

• Last Update Posted (Actual): December 26, 2023
• Last Update Submitted That Met QC Criteria: December 22, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Keywords: Overweight; Obese; Non-childbearing
• Additional Relevant MeSH Terms: Overnutrition; Nutrition Disorders; Body Weight; Overweight; Physiological Effects of Drugs; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Antipyretics; Acetaminophen
• Other Study ID Numbers: D8750C00001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

• IPD Sharing Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Access Criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No